期刊
CANCER CHEMOTHERAPY AND PHARMACOLOGY
卷 48, 期 5, 页码 383-388出版社
SPRINGER-VERLAG
DOI: 10.1007/s002800100318
关键词
ERK; cisplatin; p53; apoptosis
资金
- NCRR NIH HHS [P20RR11825] Funding Source: Medline
The extracellular signal-regulated kinase (ERK) pathway is among several signal transduction pathways that are activated in response to exposure to the DNA damage-inducing chemotherapeutic agent cisplatin. We have previously reported that inhibition of cisplatin-induced ERK activity enhances sensitivity to cisplatin. Furthermore, we have demonstrated that cisplatin-induced ERK activation is required for optimal p53 protein accumulation following cisplatin-induced DNA damage. In the present study, we expanded our investigations to examine the effect of cisplatin-induced ERK activation on the expression of p53-targeted genes that have been shown to be important in the cellular response to DNA damage including Bax, Bcl-2, Bcl-(xl), Cyclin G, Gadd45, p21(WAF1), and Mdm.2. In the ovarian carcinoma cell line A2780, cisplatin was shown to induce expression of p21(WAF1), Gadd45 and Mdm2, but cisplatin had no effect on expression of Bax, Bcl-2, Bcl-(xl), or Cyclin G. Inhibition of cisplatin-induced ERK activity by PD98059 resulted in decreased levels of p21(WAF1), Gadd45 and Mdm2. These results provide evidence that ERK activity during the cisplatin DNA damage response, regulates in part, these cell cycle control (p21(WAF1), Gadd45), DNA repair (Gadd45) and p53-regulatory (Mdm2) proteins.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据